| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,800,000 |
| Market
Cap: |
146.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.4 - $9.48 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kodiak Sciences is a biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer conjugate for the treatment in retinal vascular diseases including wet age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion. Co.'s pipeline, including product candidates KSI-501 and KSI-601, are used for other needs in retina such as dry AMD and glaucoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,379,445 |
| Total Buy Value |
$0 |
$0 |
$0 |
$9,508,745 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
0 |
0 |
7,587 |
15,417 |
| Total Sell Value |
$0 |
$0 |
$70,517 |
$126,006 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
4 |
8 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ehrlich Jason |
See Remarks |
• – – |
2023-06-16 |
4 |
AS |
$9.23 |
$20,841 |
D/D |
(2,258) |
61,924 |
|
-84% |
|
| Borgeson John A. |
See Remarks |
• – – |
2023-06-16 |
4 |
AS |
$9.23 |
$25,373 |
D/D |
(2,749) |
178,077 |
|
-84% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2023-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,494 |
64,182 |
|
- |
|
| Borgeson John A. |
See Remarks |
• – – |
2023-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,494 |
180,826 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2023-06-14 |
4 |
AS |
$9.42 |
$10,663 |
D/D |
(1,132) |
58,688 |
|
-83% |
|
| Borgeson John A. |
See Remarks |
• – – |
2023-06-14 |
4 |
AS |
$9.42 |
$13,640 |
D/D |
(1,448) |
175,332 |
|
-83% |
|
| Borgeson John A. |
See Remarks |
• – – |
2023-06-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,025 |
176,780 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2023-06-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,900 |
59,820 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2022-06-17 |
4 |
AS |
$7.02 |
$16,020 |
D/D |
(2,282) |
56,920 |
|
-11% |
|
| Borgeson John A. |
See Remarks |
• – – |
2022-06-17 |
4 |
AS |
$7.02 |
$19,642 |
D/D |
(2,798) |
173,755 |
|
-11% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2022-06-15 |
4 |
AS |
$7.21 |
$8,688 |
D/D |
(1,205) |
59,202 |
|
-3% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2022-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,494 |
60,407 |
|
- |
|
| Borgeson John A. |
See Remarks |
• – – |
2022-06-15 |
4 |
AS |
$7.21 |
$11,139 |
D/D |
(1,545) |
176,553 |
|
-3% |
|
| Borgeson John A. |
See Remarks |
• – – |
2022-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,494 |
178,098 |
|
- |
|
| Baker Felix |
Director |
– • • |
2022-06-06 |
4 |
B |
$7.75 |
$2,361,093 |
I/I |
303,917 |
15,967,504 |
2.25 |
-14% |
|
| Baker Felix |
Director |
– • • |
2022-06-03 |
4 |
B |
$7.93 |
$812,481 |
I/I |
102,200 |
15,695,640 |
2.25 |
-11% |
|
| Baker Felix |
Director |
– • • |
2022-06-02 |
4 |
B |
$7.51 |
$1,274,594 |
I/I |
166,232 |
15,604,214 |
2.25 |
-11% |
|
| Baker Felix |
Director |
– • • |
2022-05-27 |
4 |
B |
$6.64 |
$1,071,030 |
I/I |
155,940 |
15,455,507 |
2.25 |
8% |
|
| Baker Felix |
Director |
– • • |
2022-05-26 |
4 |
B |
$6.71 |
$628,583 |
I/I |
93,322 |
15,316,021 |
2.25 |
17% |
|
| Baker Felix |
Director |
– • • |
2022-05-25 |
4 |
B |
$6.53 |
$664,135 |
I/I |
101,144 |
15,232,546 |
2.25 |
20% |
|
| Baker Felix |
Director |
– • • |
2022-05-18 |
4 |
B |
$5.95 |
$1,335,419 |
I/I |
223,766 |
15,142,074 |
2.25 |
34% |
|
| Baker Felix |
Director |
– • • |
2022-05-17 |
4 |
B |
$5.99 |
$663,571 |
I/I |
110,824 |
14,942,601 |
2.25 |
25% |
|
| Baker Felix |
Director |
– • • |
2022-05-16 |
4 |
B |
$5.71 |
$697,839 |
I/I |
122,100 |
14,843,809 |
2.25 |
34% |
|
| Perlroth Victor |
Chairman and CEO |
• • • |
2022-02-25 |
4 |
S |
$8.99 |
$3,055,988 |
D/D |
(340,000) |
2,168,038 |
|
-14% |
|
| Perlroth Victor |
Chairman and CEO |
• • • |
2022-02-24 |
4 |
S |
$9.20 |
$9,201,700 |
D/D |
(1,000,000) |
2,508,038 |
|
11% |
|
153 Records found
|
|
Page 1 of 7 |
|
|
0.09 (2.98%) 
